<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<oembed><version>1.0</version><type>rich</type><width>560px</width><height>140px</height><title>Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial</title><url>https://www.myelomasociety.org/phase-2-study-of-teclistamab-based-induction-regimens-in-patients-with-transplant-eligible-te-newly-diagnosed-multiple-myeloma-ndmm-results-from-the-gmmg-hd10-dsmm-xx-majestec-5-trial/</url><author_name>IMSound</author_name><author_url>https://www.myelomasociety.org</author_url><thumbnail_url>https://www.myelomasociety.org/wp-content/uploads/2024/07/IMSound-Logo-only-v2.png</thumbnail_url><html>&lt;iframe width="560px" height="140px" src="https://www.myelomasociety.org/phase-2-study-of-teclistamab-based-induction-regimens-in-patients-with-transplant-eligible-te-newly-diagnosed-multiple-myeloma-ndmm-results-from-the-gmmg-hd10-dsmm-xx-majestec-5-trial/?standalonePlayer"&gt;&lt;/iframe&gt;</html></oembed>
